Your browser doesn't support javascript.
loading
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors.
Huang, Junzhe; Lei, Changhui; Hsi, David H; Zheng, Minjuan; Ma, Hui; Ta, Shengjun; Hu, Rui; Han, Chao; Li, Wenxia; Li, Jing; Qu, Dong; Ruan, Fangqi; Wang, Jing; Wang, Bo; Zhao, Xueli; Liu, Jiao; Zhao, Lina; Wang, Zhe; Yang, Jian; Liu, Liwen.
Afiliación
  • Huang J; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Lei C; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Hsi DH; Heart & Vascular Institute, Stamford Hospital, Connecticut, USA.
  • Zheng M; Columbia University College of Physicians & Surgeons, New York, New York, USA.
  • Ma H; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Ta S; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Hu R; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Han C; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Li W; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Li J; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Qu D; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Ruan F; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Wang J; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Wang B; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Zhao X; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Liu J; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Zhao L; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Wang Z; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Radiotherapy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Yang J; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Liu L; Xijing Ultrasound Interventional Treatment Center for Cancer, Department of Cardiac Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
JACC CardioOncol ; 6(4): 560-571, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39239332
ABSTRACT

Background:

Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option.

Objectives:

This study aimed to evaluate the safety and efficacy of TARFACT.

Methods:

Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation.

Results:

The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm (P = 0.007); and the mean width decreased from 5.0 ± 2.1 cm to 2.5 ± 0.7 cm (P = 0.041). NYHA functional class also improved median (IQR) decreased from 3.0 (1.5) to 2.0 (1.0) (P = 0.038), Peak E-wave on echocardiography showed a mean increase from 64.4 ± 15.7 cm/s to 76.6 ± 18.6 cm/s (P = 0.008), and NT-pro BNP levels had a median (IQR) reduction from 115.7 (252.1) pg/mL to 55.0 (121.6) pg/mL (P = 0.043).

Conclusions:

TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; NCT02815553).
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JACC CardioOncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JACC CardioOncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos